Key result
Metabolic syndrome shows no independent association with prolonged time to depression remission.
Why the study?
Does metabolic syndrome reduce the rate of remission from depression in older adults treated with venlafaxine?
Population
435 adults aged 60 and older (mean age 69.1) with major depressive disorder (MDD)
Comparison
Open-label, protocolized treatment with… vs Patients without metabolic syndrome
Design
Cohort, Open-label
Follow-up
12 or more weeks
Authors
Loading...
Metabolic syndrome should not yet alter venlafaxine decisions in older adults; leaves open diastolic blood pressure as an independent remission predictor.
Cohort (n=435)
Open-label
Yes
Does metabolic syndrome reduce the rate of remission from depression in older adults treated with venlafaxine?
Hazard Ratio: 0.71 (95% CI 0.52–0.95)
Metabolic syndrome is associated with greater depression severity and chronicity in older adults, which accounts for poorer antidepressant response, though higher diastolic blood pressure independently predicts delayed remission.
Mulvahill et al. (2017) conducted a cohort in major depressive disorder (MDD) (n=435). Metabolic syndrome (MetS) vs. No metabolic syndrome was evaluated on Time to remission from depression (HR 0.71, 95% CI 0.52-0.95). Metabolic syndrome was associated with prolonged time to remission from depression in unadjusted analysis (HR 0.71; 95% CI 0.52-0.95), but this relationship was not significant after adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: